RxDoctor Payments Data

Obaid Rehman, MD

Pulmonary Disease · Savannah, GANPI 1255367157

Payments from drug & device makers

$10,988in general payments, 2019–2025

Across 512 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Pulmonx Corporation$2K
  • AstraZeneca$1K
  • Regeneron Healthcare Solutions, Inc.$680
  • Actelion Pharmaceuticals US, Inc.$571
  • Sanofi$533
  • plus $5K from 34 others

What the payments were for

  • Travel & lodging$1,09810%
  • Food & beverage$9,57687%
  • Education$3153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,988 in reported general payments places this provider in the 70th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$291,626
Medicare patients
735
Services billed
3,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter341$261,737
Dupixent PenDupilumab51$231,755
OpsumitMacitentan17$203,936
Dupixent SyringeDupilumab20$73,601
Breztri AerosphereBudesonide/Glycopyr/Formoterol70$62,491
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr74$32,904
Stiolto RespimatTiotropium Br/Olodaterol Hcl48$32,066
Ambrisentan24$29,877
Breo ElliptaFluticasone/Vilanterol64$28,724
EliquisApixaban29$26,140
Spiriva RespimatTiotropium Bromide28$17,951
SymbicortBudesonide/Formoterol Fumarate46$10,225
Advair HfaFluticasone Propion/Salmeterol19$8,517
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$6,568
Spiriva HandihalerTiotropium Bromide11$6,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,751$323,365479 claims
Actelion Pharmaceuticals US, Inc.Opsumit$571$203,93617 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$1,398$79,284127 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$473$50,01876 claims
PfizerEliquis$42$26,14029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →